The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent adverse events occurred in 80% and 81% of dazukibart 150 mg and 160 mg groups.

Dermatomyositis is a rare inflammatory disease ... Hence, Dr Himanshi Chaudhary insisted that early diagnosis and treatment ...

Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.

Patients often get better with treatment. But while taking these medications, it's important to be careful to avoid getting ...

Received FDA orphan drug designation for the treatment of dermatomyositis in April 2017. Received FDA approval for the treatment of dermatomyositis in adults in July 2021. The mechanism of action ...

Achievement of cancer remission was associated with dermatomyositis complete clinical response among patients with cancer-associated DM.

Lundberg agrees: “It would be very interesting to test treatment with IL-6 antibodies in patients with polymyositis, and probably also dermatomyositis.” ...

Learn about dermatomyositis and the remarkable journey of Audrey Gouskos. Discover how St. Michael's Hospital has provided ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...